Literature DB >> 17803026

Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model.

David Mathieu1, Roger Lecomte, Ana Maria Tsanaclis, Annie Larouche, David Fortin.   

Abstract

INTRODUCTION: Adequate animal glioma models are mandatory for the pursuit of preclinical research in neuro-oncology. Many implantation models have been described, but none perfectly emulate human malignant gliomas. This work reports our experience in standardizing, optimizing and characterizing the Fischer/F98 glioma model on the clinical, pathological, radiological and metabolic aspects.
MATERIALS AND METHODS: F98 cells were implanted in 70 Fischer rats, varying the quantity of cells and volume of implantation solution, and using a micro-infusion pump to minimize implantation trauma, after adequate coordinates were established. Pathological analysis consisted in hematoxylin and eosin (H&E) staining and immunohistochemistry for GFAP, vimentin, albumin, TGF-bl, TGF-b2, CD3 and CD45. Twelve animals were used for MR imaging at 5, 10, 15 and 20 days. Corresponding MR images were compared with pathological slides. Two animals underwent 18F-FDG and 11C-acetate PET studies for metabolic characterization of the tumors.
RESULTS: Implantation with 1 x 10(4) cells produced a median survival of 26 days and a tumor take of 100%. Large infiltrative neoplasms with a necrotic core were seen on H&E. Numerous mitosis, peritumoral infiltrative behavior, and neovascular proliferation were also obvious. GFAP and vimentin staining was positive inside the tumor cells. Albumin staining was observed in the extracellular space around the tumors. CD3 staining was negligible. The MR images correlated the pathologic findings. 18F-FDG uptake was strong in the tumors.
CONCLUSION: The standardized model described in this study behaves in a predictable and reproducible fashion, and could be considered for future pre-clinical studies. It adequately mimics the behavior of human malignant astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803026     DOI: 10.1017/s0317167100006715

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  30 in total

1.  Imaging, autoradiography, and biodistribution of (188)Re-labeled PEGylated nanoliposome in orthotopic glioma bearing rat model.

Authors:  Feng-Yun J Huang; Te-Wei Lee; Chih-Hao K Kao; Chih-Hsien Chang; Xiaoning Zhang; Wan-Yu Lee; Wan-Jou Chen; Shu-Chi Wang; Jem-Mau Lo
Journal:  Cancer Biother Radiopharm       Date:  2011-12       Impact factor: 3.099

2.  Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain.

Authors:  Gabriel Charest; Léon Sanche; David Fortin; David Mathieu; Benoit Paquette
Journal:  J Neurooncol       Date:  2013-09-13       Impact factor: 4.130

Review 3.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Authors:  Rolf F Barth; Balveen Kaur
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

4.  Engineering Controlled Peritumoral Inflammation to Constrain Brain Tumor Growth.

Authors:  Tarun Saxena; Johnathan G Lyon; S Balakrishna Pai; Daniel Pare; Jessica Amero; Lohitash Karumbaiah; Sheridan L Carroll; Eric Gaupp; Ravi V Bellamkonda
Journal:  Adv Healthc Mater       Date:  2018-12-11       Impact factor: 9.933

5.  Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption.

Authors:  Marie Blanchette; Luc Tremblay; Martin Lepage; David Fortin
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

6.  Convection-enhancement delivery of platinum-based drugs and Lipoplatin(TM) to optimize the concomitant effect with radiotherapy in F98 glioma rat model.

Authors:  Minghan Shi; David Fortin; Léon Sanche; Benoit Paquette
Journal:  Invest New Drugs       Date:  2015-03-18       Impact factor: 3.850

7.  A combined diffusion tensor imaging and Ki-67 labeling index study for evaluating the extent of tumor infiltration using the F98 rat glioma model.

Authors:  Kai Wang; Tingting Ha; Xuzhu Chen; Shaowu Li; Lin Ai; Jun Ma; Jianping Dai
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

Review 8.  Molecular targeting of glioblastoma: Drug discovery and therapies.

Authors:  Ren-Yuan Bai; Verena Staedtke; Gregory J Riggins
Journal:  Trends Mol Med       Date:  2011-03-14       Impact factor: 11.951

9.  High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide.

Authors:  Gregory A Christoforidis; Ming Yang; Marinos S Kontzialis; Douglas G Larson; Amir Abduljalil; Michelle Basso; Weilian Yang; Abhik Ray-Chaudhury; Johannes Heverhagen; Michael V Knopp; Rolf F Barth
Journal:  Invest Radiol       Date:  2009-07       Impact factor: 6.016

10.  Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation.

Authors:  Gabriel Charest; Benoit Paquette; David Fortin; David Mathieu; Léon Sanche
Journal:  J Neurooncol       Date:  2009-09-17       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.